Multicenter Clinical Validation of PITX2 Methylation as a Prostate Specific Antigen Recurrence Predictor in Patients With Post-Radical Prostatectomy Prostate Cancer
Multicenter Clinical Validation of PITX2 Methylation as a Prostate Specific Antigen Recurrence Predictor in Patients With Post-Radical Prostatectomy Prostate Cancer
复制标题
DOI：
10.1016/j.juro.2010.03.012
复制
发表时间：
2010-07-01
影响因子：
6.6
通讯作者：
Castanos-Velez, Esmeralda
中科院分区：
文献类型：
--
作者：
Banez, Lionel L.;Sun, Leon;Castanos-Velez, Esmeralda
目的：根治性前列腺切除术是治疗临床上局限性前列腺癌的有效方法。然而，15% - 30%接受根治性前列腺切除术的男性会出现生化复发。我们之前报道了使用常规检测PITX2基因启动子甲基化的预后潜力。在当前的研究中，我们在多机构环境中使用一种新的基于微阵列的平台验证了PITX2甲基化状态作为根治性前列腺切除术后生化复发预测因子。材料和方法：采用定制的EpiChip (TM) PITX2芯片，对来自4家机构的476名患者的前列腺切除术肿瘤组织样本进行福尔马林固定、石蜡包埋，评估PITX2甲基化状态。采用对数秩检验和Cox回归控制前列腺癌特征，评估PITX2甲基化与生化复发之间的关系。结果：在多变量分析中，高甲基化状态男性的生化复发风险明显高于低甲基化状态男性(HR 3.0, 95% CI 2.0-4.5, p
Purpose: Radical prostatectomy is potentially curative in patients with clinically localized prostate cancer. However, biochemical recurrence affects 15% to 30% of men who undergo radical prostatectomy. We previously reported the prognostic potential of PITX2 gene promoter methylation using conventional assays. In the current study we validated PITX2 methylation status as a biochemical recurrence predictor after radical prostatectomy using a novel microarray based platform in a multi-institutional setting.Materials and Methods: PITX2 methylation status was assessed in formalin fixed, paraffin embedded prostatectomy tumor tissue samples from 476 patients from a total of 4 institutions on customized EpiChip (TM) PITX2 microarrays. Associations between PITX2 methylation and biochemical recurrence were assessed using the log rank test and Cox regression controlling for prostate cancer features.Results: On multivariate analysis men with high methylation status were at significantly higher risk for biochemical recurrence than those with low methylation status (HR 3.0, 95% CI 2.0-4.5, p